Cyclin-Dependent Kinase Inhibitors in the Rare Subtypes of Melanoma Therapy

被引:1
|
作者
Kaszubski, Jonatan [1 ]
Gagat, Maciej [2 ,3 ]
Grzanka, Alina [2 ]
Wawrzyniak, Agata [4 ]
Niklinska, Wieslawa [5 ]
Lapot, Magdalena [3 ]
Zuryn, Agnieszka [2 ]
机构
[1] Nicolaus Copernicus Univ Torun, Fac Med, Dept Histol & Embryol, Coll Medicum Bydgoszcz,Vasc Biol Student Res Club, PL-85067 Bydgoszcz, Poland
[2] Nicolaus Copernicus Univ Torun, Fac Med, Dept Histol & Embryol, Coll Med Bydgoszcz, PL-85067 Bydgoszcz, Poland
[3] Mazovian Acad Plock, Fac Med, Coll Med, PL-09402 Plock, Poland
[4] Univ Rzeszow, Inst Med Sci, Coll Med Sci, Dept Histol & Embryol, PL-35310 Rzeszow, Poland
[5] Med Univ Bialystok, Dept Histol & Embryol, PL-15269 Bialystok, Poland
来源
MOLECULES | 2024年 / 29卷 / 22期
关键词
melanoma; rare subtypes of melanoma; mucosal melanoma; uveal melanoma; acral melanoma; cyclin-dependent kinases (CDKs); CDK inhibitors (CDKIs); CDK4/6; CDK7/9; CDK2; ACRAL MELANOMA; UVEAL MELANOMA; DESMOPLASTIC MELANOMA; GENETIC ABERRATIONS; P16; EXPRESSION; MAPK PATHWAY; DISTINCT; CANCER; COMBINATION; PROTEINS;
D O I
10.3390/molecules29225239
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Melanoma occurs in various forms and body areas, not only in the cutis, but also in mucous membranes and the uvea. Rarer subtypes of that cancer differ in genomic aberrations, which cause their minor sensibility to regular cutaneous melanoma therapies. Therefore, it is essential to discover new strategies for treating rare forms of melanoma. In recent years, interest in applying CDK inhibitors (CDKIs) in cancer therapy has grown, as they are able to arrest the cell cycle and inhibit cell proliferation. Current studies highlight selective CDK4/6 inhibitors, like palbociclib or abemaciclib, as a very promising therapeutic option, since they were accepted by the FDA for advanced breast cancer treatment. However, cells of every subtype of melanoma do not react to CDKIs the same way, which is partly because of the genetic differences between them. Herein, we discuss the past and current research relevant to targeting various CDKs in mucosal, uveal and acral melanomas. We also briefly describe the issue of amelanotic and desmoplastic types of melanoma and the need to do more research to discover cell cycle dysregulations, which cause the growth of the mentioned forms of cancer.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Targeting the cyclin-dependent kinase 5 in metastatic melanoma
    Sharma, Samanta
    Zhang, Tian
    Michowski, Wojciech
    Rebecca, Vito W.
    Xiao, Min
    Ferretti, Roberta
    Suski, Jan M.
    Bronson, Roderick T.
    Paulo, Joao A.
    Frederick, Dennie
    Fassl, Anne
    Boland, Genevieve M.
    Geng, Yan
    Lees, Jacqueline A.
    Medema, Rene H.
    Herlyn, Meenhard
    Gygi, Steven P.
    Sicinski, Piotr
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (14) : 8001 - 8012
  • [32] Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy
    Liang, Hanzhi
    Du, Jintong
    Elhassan, Reham M.
    Hou, Xuben
    Fang, Hao
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (01) : 61 - 76
  • [33] Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
    Roberts, Patrick J.
    Bisi, John E.
    Strum, Jay C.
    Combest, Austin J.
    Darr, David B.
    Usary, Jerry E.
    Zamboni, William C.
    Wong, Kwok-Kin
    Perou, Charles M.
    Sharpless, Norman E.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (06): : 476 - 487
  • [34] Cyclin-Dependent Kinase Modulators and Cancer Therapy
    Gallorini, Marialucia
    Cataldi, Amelia
    di Giacomo, Viviana
    BIODRUGS, 2012, 26 (06) : 377 - 391
  • [35] Anti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges
    Reinius, Marika A. V.
    Smyth, Elizabeth
    EXPERT REVIEWS IN MOLECULAR MEDICINE, 2021, 23
  • [36] Cyclin-Dependent Kinase Modulators and Cancer Therapy
    Marialucia Gallorini
    Amelia Cataldi
    Viviana di Giacomo
    BioDrugs, 2012, 26 (6) : 377 - 391
  • [37] Emerging drug profile: cyclin-dependent kinase inhibitors
    Blachly, James S.
    Byrd, John C.
    LEUKEMIA & LYMPHOMA, 2013, 54 (10) : 2133 - 2143
  • [38] Cyclin-Dependent Kinase Inhibitors and the Treatment of Gastrointestinal Cancers
    Mikhail, Sameh
    Albanese, Christopher
    Pishvaian, Michael J.
    AMERICAN JOURNAL OF PATHOLOGY, 2015, 185 (05): : 1185 - 1197
  • [39] Discovery and Development of Cyclin-Dependent Kinase 8 Inhibitors
    Lv, Xiao
    Tian, Yongbing
    Li, Shiyu
    Cheng, Kai
    Huang, Xufeng
    Kong, Haiyan
    Liao, Chenzhong
    Xie, Zhouling
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (32) : 5429 - 5443
  • [40] Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitors
    Verma, S
    Nagarathnam, D
    Shao, JX
    Zhang, L
    Zhao, J
    Wang, YM
    Li, TD
    Mull, E
    Enyedy, I
    Wang, CG
    Zhu, QM
    Altieri, M
    Jordan, J
    Dang, TTA
    Reddy, S
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (08) : 1973 - 1977